2023
Racial, ethnic, and sex-based disparities among high-risk individuals undergoing pancreatic cancer surveillance.
Klute K, Lucas A, Brand R, Everett J, Farrell J, Hawthorne K, Kaul V, Kupfer S, Paiella S, Simeone D, Sussman D, Zogopoulos G, Kastrinos F, Katona B, Consortium A. Racial, ethnic, and sex-based disparities among high-risk individuals undergoing pancreatic cancer surveillance. Journal Of Clinical Oncology 2023, 41: 687-687. DOI: 10.1200/jco.2023.41.4_suppl.687.Peer-Reviewed Original ResearchHigh-risk individualsSex-based disparitiesFamilial pancreatic cancerPDAC surveillancePancreatic cancer surveillancePeutz-Jeghers syndromeRates of consentSex-based differencesMedian ageAshkenazi Jewish ancestryMulticenter studyProspective studyCancer surveillancePancreatic cancerFamily historyLarge cohortMelanoma syndromeHereditary pancreatitisEarly detection researchStudy participantsEarly detectionStudy periodGermline DNACohortPDACPancreatic imaging findings from the PRECEDE study: A large high-risk heritable cohort for pancreatic cancer.
Haimi I, Zogopoulos G, Dettwyler S, Everett J, Bi Y, Brand R, Chung D, Farrell J, Grossberg A, Kastrinos F, Katona B, Klute K, Kupfer S, Lucas A, Paiella S, Parmigiani G, Permuth J, Sears R, Sussman D, Simeone D, Consortium P. Pancreatic imaging findings from the PRECEDE study: A large high-risk heritable cohort for pancreatic cancer. Journal Of Clinical Oncology 2023, 41: 689-689. DOI: 10.1200/jco.2023.41.4_suppl.689.Peer-Reviewed Original ResearchHigh-risk individualsPancreatic ductal adenocarcinomaPathogenic germline variantsFamilial pancreatic cancerCohort 1Worrisome featuresPancreatic cancerMain pancreatic duct diameterSolid massPancreatic duct diameterStandardized image acquisitionPGV groupGermline testingDuct stricturesIncurable stageMultiple cystsPancreatic abnormalitiesStandardized data collection systemNeuroendocrine tumorsDuctal adenocarcinomaCommon abnormalityFamily historyBenign lesionsLethal cancersPDAC risk
2022
The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer.
Zogopoulos G, Bi Y, Brand R, Chung D, Earl J, Farrell J, Graff J, Kastrinos F, Katona B, Klute K, Koptiuch C, Kupfer S, Kwon R, Lindberg J, Lowy A, Lucas A, Paiella S, Permuth J, Sears R, Simeone D, Consortium T. The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer. Journal Of Clinical Oncology 2022, 40: e16239-e16239. DOI: 10.1200/jco.2022.40.16_suppl.e16239.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaPathogenic germline variantsFamilial pancreatic cancerCancer predisposition genesCohort studyPancreatic cancerClinical dataAnnual surveillanceEffective early detection strategiesHigh-quality clinical dataHigh-risk premalignant lesionsModifiers of riskInternational cohort studyProspective cohort studyEarly-stage diseaseOverall survival rateEarly detection strategiesEarly-stage cancerBlood sample collectionRelevant clinical populationContribution of heritabilityPenetrance of diseaseQuality clinical dataParticipants ages 18Germline testing
2021
ID: 3524866 ENDOSCOPIC ULTRASOUND - FINE NEEDLE BIOPSY (EUS-FNB) DERIVED HUMAN ORGANOID MODELS IN PANCREATIC CANCER: CLINICAL AND TECHNICAL PREDICTORS OF SUCCESS
Yoo J, Nair G, Shorr E, LaComb J, Kesar V, Foster G, Joshi N, Farrell J, Buscaglia J. ID: 3524866 ENDOSCOPIC ULTRASOUND - FINE NEEDLE BIOPSY (EUS-FNB) DERIVED HUMAN ORGANOID MODELS IN PANCREATIC CANCER: CLINICAL AND TECHNICAL PREDICTORS OF SUCCESS. Gastrointestinal Endoscopy 2021, 93: ab247-ab248. DOI: 10.1016/j.gie.2021.03.535.Peer-Reviewed Original Research
2020
Pancreatic Cancer; Biomolecular and Genetic Aspects
Yoo J, Farrell J. Pancreatic Cancer; Biomolecular and Genetic Aspects. 2020, 30-38. DOI: 10.1016/b978-0-12-801238-3.65864-6.Peer-Reviewed Original ResearchPancreatic cancerGenetic aspectsNext-generation sequencingTranscriptomic analysisGenomic investigationsKey driver mutationsRecent translational advancesOverall survival rateMutational landscapeDiscrete molecular subtypesGeneration sequencingSpecific therapyLethal malignancyMolecular subtypesDisease processDriver mutationsSurvival rateTranslational advancesCancerPrecision medicineBiomolecularSequencingMutationsPathwayPatients
2019
67 Appraisal of Follow-up Protocols and Outcomes of High Risk Pancreatic Cancer Surveillance Programs: A Systematic Review and Meta-Analysis
Chhoda A, Mukherjee E, Wattamwar K, Kastrinos F, Farrell J. 67 Appraisal of Follow-up Protocols and Outcomes of High Risk Pancreatic Cancer Surveillance Programs: A Systematic Review and Meta-Analysis. The American Journal Of Gastroenterology 2019, 114: s40-s41. DOI: 10.14309/01.ajg.0000589800.17291.ef.Peer-Reviewed Original ResearchHigh-risk individualsCross-sectional imagingEndoscopic ultrasoundPancreatic cancerDiagnostic rateSectional imagingSystematic reviewPt-yrNew lesionsBaseline imagingAdvanced pathologyCumulative progression rateCancer Surveillance ProgramOptimal imaging modalityPre-existing abnormalitiesSignificant differencesOutcomes of interestRandom-effects modelFirst systematic reviewUncontrolled studiesProspective studySubgroup analysisSurveillance protocolHistologic diagnosisProgression rateUpdated international Cancer of the Pancreas Screening (CAPS) consortium guidelines on the management of patients with increased risk for familial pancreatic cancer
Overbeek K, Canto M, Bartsch D, Brand R, Carrato A, Del Chiaro M, Farrell J, Fishman E, Fockens P, Gress T, van Hooft J, Kastrinos F, Rustgi A, Syngal S, Vasen H, Cahen D, Bruno M, Goggins M, Consortium I. Updated international Cancer of the Pancreas Screening (CAPS) consortium guidelines on the management of patients with increased risk for familial pancreatic cancer. Pancreatology 2019, 19: s56-s57. DOI: 10.1016/j.pan.2019.05.143.Peer-Reviewed Original ResearchSa1350 – Updated International Cancer of the Pancreas Screening (CAPS) Consortium Guidelines on the Management of Patients with Increased Risk for Familial Pancreatic Cancer
Overbeek K, Canto M, Bartsch D, Brand R, Carrato A, Del Chiaro M, Farrell J, Fishman E, Fockens P, Gress T, van Hooft J, Kastrinos F, Rustgi A, Syngal S, Vasen H, Cahen D, Bruno M, Goggins M. Sa1350 – Updated International Cancer of the Pancreas Screening (CAPS) Consortium Guidelines on the Management of Patients with Increased Risk for Familial Pancreatic Cancer. Gastroenterology 2019, 156: s-323. DOI: 10.1016/s0016-5085(19)37637-1.Peer-Reviewed Original Research
2017
Advanced Endoscopic Procedures
Farrell J. Advanced Endoscopic Procedures. 2017, 151-169. DOI: 10.1007/978-3-319-58256-6_8.Peer-Reviewed Original ResearchAdvanced endoscopic proceduresEndoscopic retrograde cholangiopancreatographyPancreatic cancerEndoscopic proceduresEndoscopic ultrasoundMultidisciplinary management approachManagement of patientsPalliation of patientsEndoscopic enteral stent placementEnteral stent placementRetrograde cholangiopancreatographySurgical approachStent placementCancerPatientsPalliationCholangiopancreatographyDiagnosis
2011
Su1384 Development and Validation of an EUS-FNA-Based Predictive Marker of Gemcitabine Response in Pancreatic Cancer
Farrell J, Wong J, Donahue T, Rao J. Su1384 Development and Validation of an EUS-FNA-Based Predictive Marker of Gemcitabine Response in Pancreatic Cancer. Gastrointestinal Endoscopy 2011, 73: ab249-ab250. DOI: 10.1016/j.gie.2011.03.437.Peer-Reviewed Original Research
2009
Salivary biomarkers for pancreatic cancer detection
Wong D, Zhang L, Farrell J, Zhou H, Elashoff D, Gao K, Paster B. Salivary biomarkers for pancreatic cancer detection. Journal Of Clinical Oncology 2009, 27: 4630-4630. DOI: 10.1200/jco.2009.27.15_suppl.4630.Peer-Reviewed Original ResearchPancreatic cancer patientsHuman Oral Microbe Identification MicroarrayPancreatic cancer detectionLogistic regression modelsCancer patientsPancreatic cancerSalivary biomarkersHealthy subjectsAUC valuesMRNA biomarkersIndependent clinical validationSaliva supernatantTypical clinical presentationCancer detectionNon-cancer subjectsRegression modelsBiomarker discovery strategySystemic cancerAffymetrix Human Genome U133Clinical presentationChronic pancreatitisInitial diagnosisCancer deathHuman Genome U133Non-invasive detection163 Ribonulceotide Reductase M2 (RRM2): Predictive Marker of Response to Gemcitabine in Pancreatic Cancer
Farrell J, Garcia M, Liu X, Ammar A, Regine W, Abrams R, Elsaleh H. 163 Ribonulceotide Reductase M2 (RRM2): Predictive Marker of Response to Gemcitabine in Pancreatic Cancer. Gastroenterology 2009, 136: a-32. DOI: 10.1016/s0016-5085(09)60146-3.Peer-Reviewed Original Research
2008
Validation of Randomization Based on Patient Genotype Results from RTOG 9704 Trial in Pancreatic Cancer and Implications for Future Trial Design
Farrell J, Bae K, Fromm M, Regine W, Abrams R, Safran H, Hoffman J, Dicker A, Elsaleh H. Validation of Randomization Based on Patient Genotype Results from RTOG 9704 Trial in Pancreatic Cancer and Implications for Future Trial Design. International Journal Of Radiation Oncology • Biology • Physics 2008, 72: s15. DOI: 10.1016/j.ijrobp.2008.06.799.Peer-Reviewed Original Research
2006
Long-term data for endoscopic ultrasound (EUS) and percutanous (PTA) guided intratumoral TNFerade gene delivery combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC)
Farrell J, Senzer N, Hanna N, Chung T, Nemunaitis J, Rosemurgy A, Javle M, Reid T, Posner M, Chang K, Macko J, Hecht J. Long-term data for endoscopic ultrasound (EUS) and percutanous (PTA) guided intratumoral TNFerade gene delivery combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC). Endoscopy 2006, 39 DOI: 10.1055/s-2006-947607.Peer-Reviewed Original ResearchLong-term data for endoscopic ultrasound (EUS) and percutanous (PTA) guided intratumoral TNFerade gene delivery combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC)
Farrell J, Senzer N, Hanna N, Chung T, Nemunaitis J, Rosemurgy A, Javle M, Reid T, Posner M, Chang K, Macko J, Hecht J. Long-term data for endoscopic ultrasound (EUS) and percutanous (PTA) guided intratumoral TNFerade gene delivery combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC). Endoscopy 2006, 39 DOI: 10.1055/s-2006-947613.Peer-Reviewed Original ResearchLong-Term Data for Endoscopic Ultrasound (EUS) and Percutanous (PTA) Guided Intratumoral TNFerade Gene Delivery Combined with Chemoradiation in the Treatment of Locally Advanced Pancreatic Cancer (LAPC)
Farrell J, Senzer N, Hecht J, Hanna N, Chung T, Nemunaitis J, Rosemurgy A, Javle M, Reid T, Posner M, Macko J, Chang K. Long-Term Data for Endoscopic Ultrasound (EUS) and Percutanous (PTA) Guided Intratumoral TNFerade Gene Delivery Combined with Chemoradiation in the Treatment of Locally Advanced Pancreatic Cancer (LAPC). Gastrointestinal Endoscopy 2006, 63: ab93. DOI: 10.1016/j.gie.2006.03.071.Peer-Reviewed Original Research
2005
5,10-METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) POLYMORPHISM AND PANCREATIC CANCER: RESULTS FROM THE RTOG 9704 PROSPECTIVE RANDOMIZED ADJUVANT TREATMENT TRIAL
Farrell J, Winter K, Van Rijnsoever M, Regine W, Abrams R, Safran H, Hoffman J, Schaeffer P, Mohiuddin M, Macdonald J, Benson A, Willett C, Elsaleh H. 5,10-METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) POLYMORPHISM AND PANCREATIC CANCER: RESULTS FROM THE RTOG 9704 PROSPECTIVE RANDOMIZED ADJUVANT TREATMENT TRIAL. Pancreas 2005, 31: 440. DOI: 10.1097/01.mpa.0000193664.86654.55.Peer-Reviewed Original ResearchTHYMIDYLATE SYNTHASE AND THYMIDINE PHOSPHORYLASE: PROTEIN EXPRESSION AND GENOTYPE IN PANCREATIC CANCER: RESULTS FROM THE RTOG 9704 PROSPECTIVE RANDOMIZED ADJUVANT TREATMENT TRIAL
Farrell J, Winter K, Van Rijnsoever M, Regine W, Abrams R, Safran H, Hoffman J, Schaeffer P, Mohiuddin M, Macdonald J, Benson A, Willett C, Elsaleh H. THYMIDYLATE SYNTHASE AND THYMIDINE PHOSPHORYLASE: PROTEIN EXPRESSION AND GENOTYPE IN PANCREATIC CANCER: RESULTS FROM THE RTOG 9704 PROSPECTIVE RANDOMIZED ADJUVANT TREATMENT TRIAL. Pancreas 2005, 31: 439-440. DOI: 10.1097/01.mpa.0000193663.09525.af.Peer-Reviewed Original ResearchENDOSCOPIC ULTRASOUND FINE NEEDLE INJECTION (EUS-FNI) OF A NOVEL GENE TRANSFER THERAPY AGAINST PANCREATIC CANCER: A SINGLE INSTITUTION EXPERIENCE
Farrell J, Macko J, Hecht J. ENDOSCOPIC ULTRASOUND FINE NEEDLE INJECTION (EUS-FNI) OF A NOVEL GENE TRANSFER THERAPY AGAINST PANCREATIC CANCER: A SINGLE INSTITUTION EXPERIENCE. Pancreas 2005, 31: 440. DOI: 10.1097/01.mpa.0000193665.94277.73.Peer-Reviewed Original Research
2004
A Novel Gene Transfer Therapy Against Pancreatic Cancer (TNFerade) Delivered by Endoscopic Ultrasound (EUS) and Percutaneous Guided Fine Needle Injection (FNI)
Chang K, Senzer N, Chung T, Hecht J, Vogel S, Rosemurgy A, Nemunaitis J, Gibbs J, Javle M, Reid T, Macko J, Kessler P, Posner M, Farrell J, Grundy L, Soetikno R, Waxman I, Hanna N. A Novel Gene Transfer Therapy Against Pancreatic Cancer (TNFerade) Delivered by Endoscopic Ultrasound (EUS) and Percutaneous Guided Fine Needle Injection (FNI). Gastrointestinal Endoscopy 2004, 59: p92. DOI: 10.1016/s0016-5107(04)00470-5.Peer-Reviewed Original Research